- Home
- MRNA vs NLY Comparison
MRNA vs NLY Comparison
Compare MRNA & NLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- NLY
- Stock Information
- Founded
- MRNA 2010
- NLY 1996
- Country
- MRNA United States
- NLY United States
- Employees
- MRNA N/A
- NLY N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- NLY Real Estate Investment Trusts
- Sector
- MRNA Health Care
- NLY Real Estate
- Exchange
- MRNA Nasdaq
- NLY Nasdaq
- Market Cap
- MRNA 10.6B
- NLY 12.6B
- IPO Year
- MRNA 2018
- NLY 1997
- Fundamental
- Price
- MRNA $26.56
- NLY $18.94
- Analyst Decision
- MRNA Hold
- NLY Buy
- Analyst Count
- MRNA 19
- NLY 11
- Target Price
- MRNA $48.13
- NLY $21.00
- AVG Volume (30 Days)
- MRNA 14.2M
- NLY 7.6M
- Earning Date
- MRNA 05-01-2025
- NLY 07-23-2025
- Dividend Yield
- MRNA N/A
- NLY 14.78%
- EPS Growth
- MRNA N/A
- NLY N/A
- EPS
- MRNA N/A
- NLY 0.93
- Revenue
- MRNA $3,177,000,000.00
- NLY $956,137,000.00
- Revenue This Year
- MRNA N/A
- NLY $324.73
- Revenue Next Year
- MRNA $8.98
- NLY $0.30
- P/E Ratio
- MRNA N/A
- NLY $20.27
- Revenue Growth
- MRNA N/A
- NLY N/A
- 52 Week Low
- MRNA $23.15
- NLY $16.60
- 52 Week High
- MRNA $158.82
- NLY $22.11
- Technical
- Relative Strength Index (RSI)
- MRNA 50.60
- NLY 44.73
- Support Level
- MRNA $25.22
- NLY $18.43
- Resistance Level
- MRNA $27.15
- NLY $19.83
- Average True Range (ATR)
- MRNA 1.61
- NLY 0.31
- MACD
- MRNA 0.26
- NLY -0.04
- Stochastic Oscillator
- MRNA 47.66
- NLY 34.00
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About NLY Annaly Capital Management Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are; the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.